See more : Chengdu Leejun Industrial Co., Ltd. (002651.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Innovent Biologics, Inc. (IVBXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innovent Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- WhiteHawk Limited (WHK.AX) Income Statement Analysis – Financial Results
- Manning Ventures Inc. (MANVF) Income Statement Analysis – Financial Results
- Avenue Therapeutics, Inc. (ATXI) Income Statement Analysis – Financial Results
- Guo Tai Epoint Software Co.,Ltd. (688232.SS) Income Statement Analysis – Financial Results
- Net One Systems Co., Ltd. (NONEF) Income Statement Analysis – Financial Results
Innovent Biologics, Inc. (IVBXF)
About Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.21B | 4.56B | 4.27B | 3.84B | 1.05B | 9.48M | 18.54M | 32.13M |
| Cost of Revenue | 1.81B | 930.99M | 573.04M | 387.76M | 124.88M | -1.31M | -71.47M | 0.00 |
| Gross Profit | 4.40B | 3.63B | 3.70B | 3.46B | 922.65M | 10.79M | 90.01M | 32.13M |
| Gross Profit Ratio | 70.89% | 79.57% | 86.58% | 89.91% | 88.08% | 113.84% | 485.54% | 100.00% |
| Research & Development | 2.23B | 2.87B | 2.48B | 1.85B | 1.29B | 1.22B | 611.92M | 384.65M |
| General & Administrative | 750.28M | 835.49M | 884.03M | 436.87M | 255.30M | 277.50M | 87.77M | 57.38M |
| Selling & Marketing | 3.10B | 2.59B | 2.73B | 1.34B | 1.19B | 136.01M | 9.94M | 5.03M |
| SG&A | 3.85B | 3.43B | 3.61B | 1.78B | 1.45B | 413.51M | 87.77M | 57.38M |
| Other Expenses | 0.00 | -90.20M | -45.13M | -130.69M | -41.38M | -4.34B | -51.01M | -123.20M |
| Operating Expenses | 5.07B | 6.21B | 6.05B | 3.50B | 2.70B | 1.56B | 643.27M | 413.27M |
| Cost & Expenses | 7.89B | 7.14B | 6.62B | 3.89B | 2.83B | 1.56B | 643.27M | 413.27M |
| Interest Income | 452.84M | 189.54M | 151.76M | 116.10M | 102.70M | 20.68M | 7.98M | 4.54M |
| Interest Expense | 98.62M | 101.70M | 62.46M | 68.35M | 59.49M | 68.97M | 57.23M | 53.80M |
| Depreciation & Amortization | 385.10M | 319.42M | 204.75M | 85.63M | 86.37M | 64.06M | 61.10M | 53.35M |
| EBITDA | -660.68M | -1.75B | -2.37B | -704.74M | -1.57B | -5.74B | -597.72M | -359.92M |
| EBITDA Ratio | -10.65% | -38.51% | -68.11% | -19.11% | -150.52% | -60,586.43% | -3,430.40% | -1,413.33% |
| Operating Income | -1.68B | -2.07B | -3.11B | -820.14M | -1.66B | -1.79B | -750.14M | -461.54M |
| Operating Income Ratio | -27.06% | -45.52% | -72.91% | -21.34% | -158.76% | -18,841.75% | -4,046.48% | -1,436.60% |
| Total Other Income/Expenses | 534.89M | -96.54M | 61.63M | -301.53M | -56.86M | -4.32B | -91.32M | -131.19M |
| Income Before Tax | -1.14B | -2.17B | -3.05B | -858.71M | -1.72B | -5.87B | -716.05M | -544.46M |
| Income Before Tax Ratio | -18.44% | -47.64% | -71.46% | -22.34% | -164.19% | -61,970.90% | -3,862.61% | -1,694.69% |
| Income Tax Expense | -116.50M | 8.80M | 87.04M | 139.71M | 56.86M | 27.48M | -244.37M | -150.97M |
| Net Income | -1.03B | -2.18B | -3.14B | -998.42M | -1.78B | -5.77B | -562.32M | -504.20M |
| Net Income Ratio | -16.56% | -47.83% | -73.50% | -25.97% | -169.62% | -60,899.99% | -3,033.33% | -1,569.40% |
| EPS | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| EPS Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.50 | -0.45 |
| Weighted Avg Shares Out | 1.56B | 1.49B | 1.45B | 1.35B | 1.18B | 334.68M | 1.12B | 1.12B |
| Weighted Avg Shares Out (Dil) | 1.56B | 1.49B | 1.46B | 1.36B | 1.18B | 334.68M | 1.12B | 1.12B |
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial Progress
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress
Source: https://incomestatements.info
Category: Stock Reports